The stock is likely to decline on the guidance miss despite a solid quarter, as the Exact Sciences acquisition dilution outweighs near-term growth. Monitor second-quarter EPS guidance of $1.25-$1.31 for signs of recovery.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 16 $95.48entry
- T+1 · 7mo ago +1.40%α +0.19% · $96.82
- T+5 · 7mo ago −3.19%α −4.18% · $92.43
- T+20 · 6mo ago −12.20%α −18.01% · $83.83
- T+60 · 4mo ago −1.62%α −9.21% · $93.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abbott Laboratories reported first-quarter 2026 adjusted EPS of $1.15, a 6% year-over-year increase, but missed consensus by $0.00. Revenue of $11.16B grew 7.8% YoY. The company lowered full-year 2026 adjusted EPS guidance to $5.38-$5.58 (from $5.55-$5.80) due to $0.20 dilution from the Exact Sciences acquisition. Despite strong growth in Established Pharmaceuticals and Medical Devices, the guidance reduction drives a bearish sentiment.
Key Financial Metrics
Key Facts
- First-quarter 2026 adjusted EPS was $1.15, missing consensus of $1.15 by $0.00 but up 6% YoY
- First-quarter 2026 revenue was $11.16B, beating consensus of $11.00B and growing 7.8% YoY
- Full-year 2026 adjusted EPS guidance was lowered to $5.38-$5.58 from $5.55-$5.80 due to $0.20 dilution from the Exact Sciences acquisition
- The company completed the acquisition of Exact Sciences, establishing a new oncology diagnostics business
- Medical Devices sales grew 13.2% YoY, driven by double-digit growth in Electrophysiology, Heart Failure, and Rhythm Management
Financial Impact
The guidance reduction of $0.20 at the midpoint implies a $0.7B annual EPS impact, offsetting the strong quarterly beat
Risk Factors
- Exact Sciences acquisition may underperform, leading to further dilution
- Integration risks from the Exact Sciences acquisition
- Continued pricing pressures in the Nutrition segment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-025365 |
| Document: abt-20260416.htm | 0001628280-26-025365 |
| Document: 0001628280-26-025365-index-headers.html | 0001628280-26-025365 |
| Document: 0001628280-26-025365-index.html | 0001628280-26-025365 |
| Document: 0001628280-26-025365.txt | 0001628280-26-025365 |
| 8-K Data (Synthetic) | 0001628280-26-025365 |
Track record
38 reports on ABT
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +17.16% at T+20 after the Jul 1, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $109.93 Now $107.45 −2.26% settles Dec 7
- Oct 27, 202620d ago ANALYST-DOWNGRADE Neutral 2/10 Entry $103.10 Now $107.45 +4.22% settles Nov 24
- Oct 27, 202621d ago Court Ruling Neutral 1/10 Entry $102.64 Now $107.45 +4.69% settles Nov 25
- Oct 21, 202626d ago Institutional Cluster Mixed 4/10 Entry $102.51 Now $107.45 +4.82% settles Nov 19
- Oct 21, 202626d ago 8-K Bullish 6/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
- Oct 21, 202626d ago 8-K Bearish 6/10 No price data
- Oct 21, 202626d ago Press Release Neutral 4/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
- Oct 20, 202628d ago Court Ruling Neutral 1/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
- Oct 16, 20264w ago Court Ruling Neutral 2/10 Entry $104.06 to $107.45 Now $107.45 +3.26% ▲ +3.26% +6.72% vs SPY
- Oct 15, 20264w ago Court Ruling Bullish 5/10 Entry $104.89 to $108.52 Now $107.45 +2.44% ▲ +3.46% +4.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers